BR112021020401A2 - Sistema de dois plasmídeos, plasmídeo auxiliar, plasmídeo vetor, usos do sistema de dois plasmídeos, métodos para controlar ou maximizar a razão de partículas completas para totais produzidas durante a produção de aav recombinante e para aumentar, otimizar ou maximizar o rendimento de aav recombinante - Google Patents

Sistema de dois plasmídeos, plasmídeo auxiliar, plasmídeo vetor, usos do sistema de dois plasmídeos, métodos para controlar ou maximizar a razão de partículas completas para totais produzidas durante a produção de aav recombinante e para aumentar, otimizar ou maximizar o rendimento de aav recombinante

Info

Publication number
BR112021020401A2
BR112021020401A2 BR112021020401A BR112021020401A BR112021020401A2 BR 112021020401 A2 BR112021020401 A2 BR 112021020401A2 BR 112021020401 A BR112021020401 A BR 112021020401A BR 112021020401 A BR112021020401 A BR 112021020401A BR 112021020401 A2 BR112021020401 A2 BR 112021020401A2
Authority
BR
Brazil
Prior art keywords
plasmid
maximizing
recombinant aav
methods
optimizing
Prior art date
Application number
BR112021020401A
Other languages
English (en)
Portuguese (pt)
Inventor
Florian Sonntag
Markus Hörer
Renée Kober
Original Assignee
Freeline Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1905263.8A external-priority patent/GB201905263D0/en
Priority claimed from EP19169121.1A external-priority patent/EP3722434B2/en
Application filed by Freeline Therapeutics Ltd filed Critical Freeline Therapeutics Ltd
Publication of BR112021020401A2 publication Critical patent/BR112021020401A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
BR112021020401A 2019-04-12 2020-04-14 Sistema de dois plasmídeos, plasmídeo auxiliar, plasmídeo vetor, usos do sistema de dois plasmídeos, métodos para controlar ou maximizar a razão de partículas completas para totais produzidas durante a produção de aav recombinante e para aumentar, otimizar ou maximizar o rendimento de aav recombinante BR112021020401A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1905263.8A GB201905263D0 (en) 2019-04-12 2019-04-12 Plasmid system
EP19169121.1A EP3722434B2 (en) 2019-04-12 2019-04-12 Plasmid system
PCT/GB2020/050947 WO2020208379A1 (en) 2019-04-12 2020-04-14 Plasmid system

Publications (1)

Publication Number Publication Date
BR112021020401A2 true BR112021020401A2 (pt) 2021-12-07

Family

ID=70295566

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021020401A BR112021020401A2 (pt) 2019-04-12 2020-04-14 Sistema de dois plasmídeos, plasmídeo auxiliar, plasmídeo vetor, usos do sistema de dois plasmídeos, métodos para controlar ou maximizar a razão de partículas completas para totais produzidas durante a produção de aav recombinante e para aumentar, otimizar ou maximizar o rendimento de aav recombinante

Country Status (11)

Country Link
US (2) US20220162642A1 (cg-RX-API-DMAC7.html)
EP (1) EP3953482A1 (cg-RX-API-DMAC7.html)
JP (1) JP7562558B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220019669A (cg-RX-API-DMAC7.html)
CN (1) CN113891942A (cg-RX-API-DMAC7.html)
AU (1) AU2020272557B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020401A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136545A1 (cg-RX-API-DMAC7.html)
IL (2) IL296544A (cg-RX-API-DMAC7.html)
SG (1) SG11202111149VA (cg-RX-API-DMAC7.html)
WO (1) WO2020208379A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020001593A (es) 2017-08-09 2020-07-13 Bioverativ Therapeutics Inc Moleculas de acido nucleico y usos de las mismas.
JP7602454B2 (ja) 2018-08-09 2024-12-18 バイオベラティブ セラピューティクス インコーポレイテッド 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
PL3722434T3 (pl) 2019-04-12 2022-12-12 Freeline Therapeutics Limited Układ plazmidowy
WO2021084276A2 (en) 2019-11-01 2021-05-06 Freeline Therapeutics Limited Factor viii construct
WO2022159702A1 (en) * 2021-01-22 2022-07-28 Biogen Ma Inc. Microtubule destabilizer additives to increase recombinant viral vector titers
WO2022182986A1 (en) * 2021-02-26 2022-09-01 Logicbio Therapeutics, Inc. Manufacturing and use of recombinant aav vectors
EP4410971A4 (en) * 2021-09-30 2025-06-04 FUJIFILM Corporation METHOD FOR PRODUCING AN ADENO-ASSOCIATED VIRUS, CELLS AND EXPRESSION VECTOR
GB202214328D0 (en) 2022-09-29 2022-11-16 Freeline Therapeutics Ltd Method
WO2024160232A1 (zh) * 2023-02-01 2024-08-08 纽福斯(苏州)生物科技有限公司 质粒包装系统及其应用
CN118633572B (zh) * 2023-03-06 2026-07-21 北京锦篮基因科技股份有限公司 神经元核内包涵体病小鼠模型构建方法及应用
WO2024223931A1 (en) * 2023-04-28 2024-10-31 AstraZeneca Ireland Limited Manufacturing and use of recombinant self-complementary aav vectors
KR20260082361A (ko) 2023-08-31 2026-06-04 디노 테라퓨틱스, 인코포레이티드 캡시드 폴리펩타이드 및 이의 사용 방법
WO2025083617A1 (en) * 2023-10-18 2025-04-24 Nanocell Therapeutics Holdings B.V. Methods and compositions for nucleic construct delivery
TW202545971A (zh) 2024-02-08 2025-12-01 美商戴諾治療公司 殼體多肽及其使用方法
TW202548023A (zh) 2024-03-14 2025-12-16 美商雅菲納治療公司 用於生產重組腺相關病毒的質體系統
EP4628576A1 (en) 2024-04-07 2025-10-08 Ascend Advanced Therapies GmbH Microrna molecules for use in methods for improving recombinant aav production
WO2025238067A1 (en) 2024-05-15 2025-11-20 Ascend Advanced Therapies Gmbh Novel vector system for aav production
EP4752226A1 (en) 2024-11-28 2026-06-03 Ascend Advanced Therapies GmbH Plasmid system for aav production
WO2026064428A2 (en) 2024-09-18 2026-03-26 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
WO2026064444A1 (en) 2024-09-18 2026-03-26 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
WO2026064442A2 (en) 2024-09-18 2026-03-26 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
WO2026109693A1 (en) 2024-11-21 2026-05-28 Ascend Advanced Therapies Ltd Method for improved aav production
WO2026122963A1 (en) 2024-12-06 2026-06-11 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10066104A1 (de) 2000-09-08 2003-01-09 Medigene Ag Wirtszellen zur Verpackung von rekombinantem Adeno-assoziiertem Virus (rAAV), Verfahren zu ihrer Herstellung und deren Verwendung
CA2453405A1 (en) * 2001-07-13 2003-01-23 University Of Iowa Research Foundation Pseudotyped adeno-associated viruses and uses thereof
AU2002352195A1 (en) * 2001-11-30 2003-06-10 Medigene Aktiengesellschaft Optimized production of viral vectors derived from paroviruses in packaging and production cells by hsv infection or treatment with dna methylation inhibitors
ES2330826B1 (es) * 2008-06-04 2010-07-26 Proyecto De Biomedicina Cima, S.L. Sistema para empaquetamiento de adenovirus de alta capacidad.
CA2754335C (en) * 2009-03-04 2019-12-24 Medigene Ag Assembly activating protein (aap) and its use for the manufacture of parvovirus particles essentially consisting of vp3
EP3795581A3 (en) 2011-08-24 2021-06-09 The Board of Trustees of the Leland Stanford Junior University New avv capsid proteins for nucleic acid transfer
EP2782596A4 (en) 2011-11-22 2015-07-29 Philadelphia Children Hospital VIRUS VECTORS FOR HIGHLY EFFICIENT TRANSGENIC ADMINISTRATION
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
WO2017096164A1 (en) 2015-12-02 2017-06-08 The Board Of Trustees Of The Leland Stanford Junior University Novel recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism
CN108048483B (zh) * 2018-01-30 2021-02-02 中国疾病预防控制中心病毒病预防控制所 复制型重组腺病毒HAdV-5载体系统及其应用

Also Published As

Publication number Publication date
IL296544A (en) 2022-11-01
AU2020272557A1 (en) 2021-12-09
SG11202111149VA (en) 2021-11-29
EP3953482A1 (en) 2022-02-16
US20260117255A1 (en) 2026-04-30
CN113891942A (zh) 2022-01-04
JP7562558B2 (ja) 2024-10-07
AU2020272557B2 (en) 2026-05-28
KR20220019669A (ko) 2022-02-17
CA3136545A1 (en) 2020-10-15
WO2020208379A1 (en) 2020-10-15
US20220162642A1 (en) 2022-05-26
IL287100A (en) 2021-12-01
JP2022530192A (ja) 2022-06-28

Similar Documents

Publication Publication Date Title
MX2021006646A (es) Vector viral adenoasociado recombinante para el suministro de genes.
PH12021551155A1 (en) Recombinant viral vectors and nucleic acids for producing the same
WO2019241535A3 (en) Anion exchange chromatography for recombinant aav production
EP4316512A3 (en) Intrathecal administration of adeno-associated-viral vectors for gene therapy
EP4345165A3 (en) Gene therapy for retinitis pigmentosa
MX2021003188A (es) Composiciones y métodos para la manufactura de vectores de terapia génica.
ZA202307880B (en) Human cytomegalovirus comprising exogenous antigens
EP3597760A3 (en) Adeno-associated virus vector
EA201692361A1 (ru) Лентивирусные векторы
PH12016501623A1 (en) Compositions for the inactivation of virus replication and methods of making and using the same
MX375365B (es) Metodos mejorados para purificacion de vecotres de aav recombinantes
EP4491733A3 (en) Modulation of aav vector transgene expression
MX2020009579A (es) Vectores de adn sintetico y metodos de uso.
MX2018005286A (es) Constructo genetico.
AU2017257169A1 (en) Evasion of neutralizing antibodies by a recombinant adeno-associated virus
WO2012142434A3 (en) Aav mediated ctla-4 gene transfer to treat sjogren's syndrome
EP4055174A4 (en) TRANSGENIC CASSETTES, AAV VECTORS AND AAV VECTORS FOR EXPRESSING HUMAN CODON-OPTIMIZED SLCA1
MX2019008105A (es) Virus.
PL3740199T3 (pl) Enkapsułkowane polimerem wektory wirusowe do terapii genetycznej
ZA202304290B (en) Nucleic acid constructs, viral vectors and viral particles
BR112016023980A2 (pt) anticorpos monoclonais recombinantes vnar que neutralizam o fator de crescimento endotelial vascular (vegf)
EP4223320A3 (en) Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3)
WO2020069320A4 (en) A method for treating an auditory neuropathy spectrum disorder
MX2022004770A (es) Vectores de virus adeno-asociados (aav) para el tratamiento de la degeneracion macular relacionada con la edad y otras enfermedades y trastornos oculares.
ZA202402156B (en) Method of obtaining a modified adeno-associated virus capsid

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ASCEND GENE AND CELL THERAPIES LTD (GB)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]